Cancer Focused Clovis Oncology Files For Bankruptcy
Cancer Focused Clovis Oncology Files For Bankruptcy
癌症集中克洛維斯腫瘤科文件破產
- Clovis Oncology Inc (NASDAQ:CLVS) has voluntarily initiated a Chapter 11 proceeding in the U.S. Bankruptcy Court and will seek to sell its assets through a court-supervised sales process.
- The Debtors have filed various "first day" motions with the Bankruptcy Court requesting customary relief that will enable them to transition into Chapter 11 without material disruption to their ordinary course operations.
- Related: Clovis Oncology Shares Nose-Dive As Potential Bankruptcy Filing Looms.
- Clovis has received a commitment of up to $75 million in a multi-draw debtor-in-possession (DIP) financing facility.
- Before the Chapter 11 filing, and subject to Bankruptcy Court approval, Clovis entered into a "stalking horse" purchase and assignment agreement with Novartis Innovative Therapies AG for FAP-2286 for an upfront payment of $50 million and up to an additional $333.75 million as development & regulatory milestones and $297 million in later sales milestones.
- Clovis is also actively engaged in discussions with several interested parties for a potential sale of one or more of its other assets.
- Price Action: CLVS shares are down 11.50% at $0.18 during the premarket session on the last check Monday.
- 克洛維斯腫瘤公司納斯達克(Sequoia Capital：CLVS)已自願向美國破產法院提起破產法第11章的訴訟，並將尋求通過法院監督的出售程式出售其資產。
- 債務人向破產法院提出了各種“第一天”動議，請求習慣上的救濟，使他們能夠過渡到破產法第11章，而不會對他們的正常運作造成實質性的幹擾。
- 相關： Clovis Oncology股價暴跌，可能申請破產.
- Clovis已經收到了高達7500萬美元的承諾，這是一項多抽頭債務人佔有(DIP)融資安排。
- 在根據破產法第11章提交破產保護申請之前，Clovis與諾華創新療法股份公司就FAP-2286簽訂了一項“跟蹤馬”購買和轉讓協定，預付款為5000萬美元，作為開發和監管里程碑的額外資金最高可達3.3375億美元，在後來的銷售里程碑中為2.97億美元。
- Clovis還積極參與與幾個感興趣的各方就可能出售其一項或多項其他資產進行談判。
- 價格行動：CLVS股價週一收盤前下跌11.50%，至0.18美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間